Title

SB-480848 (Glaxosmithkline)

Document Type

Article

Publication Date

3-1-2004

Abstract

SB-480848 is a reversible lipoprotein-associated phospholipase A 2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.

This document is currently not available here.

Share

COinS